SEC Company Response from PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075) (PMCB) — Apr 27, 2011
PharmaCyte Biotech, Inc. (PMCB) (CIK 0001157075)
Date: April 27, 2011 · CIK: 0001157075 · Accession: 0001262463-11-000049
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-68008
Referenced dates: February 15, 2011
Letter
RE:
September __, 2010 April 26, 2011
Jim Rosenberg/Senior Assistant Chief Accountant
United States
Securities and Exchange Commission
100 F. Street, N.W.
Mail Stop 4561
Washington, D.C. 20549-3561
Nuvilex, Inc.
Your Letter of February 15, 2011
Form 10-K for the Year Ended April 30, 2010
Forms 10-Q for the Quarters Ended July 31 and October 31, 2010
File No. 333-68008
Mr. Rosenberg:
This correspondence is in response to your letter dated February 15, 2011 in reference to our filings Form 10-K for the year ended April 30, 2010 and Form 10Q for the quarters ended July 31 and October 31, 2010 on the behalf of Nuvilex, Inc., File No. 333-68008.
Please accept the following responses and note that Registrant filed amended Form 10-K/A and Forms 10-Q/A on April 26, 2011.
1.
Registrant amended Note 1of Form 10-K to reflect that the independent appraisal was used to assist management with its valuation so as to avoid the false impression that the appraisal numbers formed the entire basis of management’s decision or that the restated amounts were taken directly from the appraiser.
2.
Registrant has amended the Statement of Operations in Form 10-K to list the loss on impairment as part of income from operations.
3.
Registrant has amended Item 4 for Part I of Form 10-Q for both the quarter ended July 31 and October 31, 2010 to definitively state that Registrant’s internal controls and procedures were ineffective as of the respective dates. Further, Registrant notes that Exchange Act Rules 13a-15(e) and 15d-15(e) are referenced in the disclosure.
Registrant wishes to acknowledge the following:
·
The Company is responsible for the adequacy and accuracy of the disclosures in the filing.
·
Staff comments, or changes to disclosures in response to staff comments in filings disclosed to the Staff, do not foreclose the Commission from taking any action with respect to the filing.
·
The Company may not assert the Staff comments as a defense in any proceeding initiated by the Commission or by any person under the Federal Securities Laws.
Respectfully submitted,
/s/ Patricia Gruden
Show Raw Text
CORRESP 1 filename1.htm September __, 2010 April 26, 2011 Jim Rosenberg/Senior Assistant Chief Accountant United States Securities and Exchange Commission 100 F. Street, N.W. Mail Stop 4561 Washington, D.C. 20549-3561 RE: Nuvilex, Inc. Your Letter of February 15, 2011 Form 10-K for the Year Ended April 30, 2010 Forms 10-Q for the Quarters Ended July 31 and October 31, 2010 File No. 333-68008 Mr. Rosenberg: This correspondence is in response to your letter dated February 15, 2011 in reference to our filings Form 10-K for the year ended April 30, 2010 and Form 10Q for the quarters ended July 31 and October 31, 2010 on the behalf of Nuvilex, Inc., File No. 333-68008. Please accept the following responses and note that Registrant filed amended Form 10-K/A and Forms 10-Q/A on April 26, 2011. 1. Registrant amended Note 1of Form 10-K to reflect that the independent appraisal was used to assist management with its valuation so as to avoid the false impression that the appraisal numbers formed the entire basis of management’s decision or that the restated amounts were taken directly from the appraiser. 2. Registrant has amended the Statement of Operations in Form 10-K to list the loss on impairment as part of income from operations. 3. Registrant has amended Item 4 for Part I of Form 10-Q for both the quarter ended July 31 and October 31, 2010 to definitively state that Registrant’s internal controls and procedures were ineffective as of the respective dates. Further, Registrant notes that Exchange Act Rules 13a-15(e) and 15d-15(e) are referenced in the disclosure. Registrant wishes to acknowledge the following: · The Company is responsible for the adequacy and accuracy of the disclosures in the filing. · Staff comments, or changes to disclosures in response to staff comments in filings disclosed to the Staff, do not foreclose the Commission from taking any action with respect to the filing. · The Company may not assert the Staff comments as a defense in any proceeding initiated by the Commission or by any person under the Federal Securities Laws. Respectfully submitted, /s/ Patricia Gruden Patricia Gruden Interim Chief Financial Officer